OncoAgency^™

Globally recognized medical communications agency under Inizio Medical; deep Oncology publications planning, scientific platform development, and Medical Affairs strategy capabilities.

Large (200+)

Global market leader in Hematology-Oncology business intelligence; experts in medical communications and publications.

Mid-Size (50-200)

Globally recognized medical communications agency under Inizio Medical; Oncology, hematology, and rare disease publications, advisory boards, and Medical Affairs strategy work.

Large (200+)

Scientific communications agency specializing exclusively in Oncology and hematology medical and commercial strategy, engagement, and education; acquired by Petauri Advance and operates as the Oncology medcomms anchor within the Petauri platform.

Boutique (<50)

Medical communications agency within Syneos Health Communications integrating multichannel planning, clinically driven scientific strategy, and execution.

Mid-Size (50-200)

Medical communications agency within Syneos Health Communications; builds relationships and collaboration between biopharma and HCPs in Oncology and specialty.

Mid-Size (50-200)

Global medical strategy and communications business under Lumanity; ONEE platform supports personalized HCP engagement; significant Oncology Medical Affairs work.

Large (200+)

Independent medical communications consultancy specializing in pharma medical communications strategy; thought leadership via Transforming Medical Communications podcast.

Boutique (<50)

Inizio Medical's medical excellence and AI transformation agency (iON.AI platform); supports Medical Affairs digital and content innovation across Oncology and rare disease.

Mid-Size (50-200)

Global medical communications agency network under Inizio Medical; significant Oncology publications, scientific platform development, and congress program capabilities.

Large (200+)

Full-service medical affairs agency embedded within global CRO; deep Oncology and hematology cell/gene therapy expertise.

Large (200+)

Pharmaceutical-services platform actively partnering with best-in-class companies across global market access, health systems, medical affairs, medical communications, HEOR, patient services, and data and analytics; acquired BluPrint Oncology as the Oncology medical communications anchor.

Mid-Size (50-200)

Independent medical communications and learning company; deep Medical Affairs and commercial training capabilities across Oncology and specialty therapeutic areas.

Large (200+)

Boutique Oncology consulting firm offering KOL/DOL insights and strategic advisory during Oncology congresses.

Boutique (<50)

Independent medical communications agency with extensive Oncology experience; medical writing, publications, value dossiers, and HTA submissions.

Boutique (<50)

Independent boutique scientific communications agency; agile alternative to network agencies for Oncology Medical Affairs and publications work.

Boutique (<50)

Medical communications agency with extensive Oncology and hematology content expertise; supports scientific and digital communications.

Boutique (<50)

Global healthcare communications firm rooted in medical communications; Oncology and hematology primary with cell therapy and rare disease expertise.

Mid-Size (50-200)

Oncology and rare disease KOL identification and profiling platform; programmatic mining of KOL digital behavior and scientific output.

Boutique (<50)

AI-powered Oncology KOL intelligence and data analytics platform helping pharma identify and engage cancer key opinion leaders.

Boutique (<50)

Generative and agentic AI solutions for Oncology and life sciences; Oncology RWD and AI-powered drug development acceleration.

Mid-Size (50-200)

Oncology-only real-world data company providing curated EHR data from academic and community Oncology settings for pharma commercial and HEOR teams.

Mid-Size (50-200)

The leading Oncology-only real-world data and evidence platform; curated EHR-derived datasets used by pharma and FDA regulatory submissions.

Large (200+)

IQVIA's dedicated Oncology commercial intelligence platform; global Oncology analytics specialty spanning HCP targeting to RWE.

Large (200+)

Oncology-only clinical operations platform enabling life sciences to partner with providers on clinical trials and real-world data projects.

Boutique (<50)

Oncology-only data and insights company from McKesson; access to community Oncology RWD via iKnowMed EHR and Clear Value Plus.

Large (200+)

AI-driven pharma commercial intelligence platform with roots in Oncology; provides HCP targeting and field force analytics with 7M+ HCP profiles.

Boutique (<50)

Precision Oncology platform combining biomarker testing with pharma clinical trial matching and commercial data solutions.

Boutique (<50)

AI-powered precision medicine company; 95% of top 20 pharma Oncology companies partner with Tempus for RWD genomic data and clinical trial matching.

Large (200+)

Healthcare research and analytics firm with deep Oncology commercial intelligence — HCP behavior analytics for Oncology commercial teams.

Boutique (<50)

Global management consulting and analytics firm with dedicated Oncology commercial practice including field force and brand analytics.

Large (200+)

Global commercial and medical services partner with Oncology journals and publishing assets reaching 40,000+ HCPs; AnswerY AI platform powers medical communications.

Large (200+)

Specialty healthcare advertising agency dedicated to Oncology and rare diseases; emerged from Harrison & Star in 2008 as a conflict shop for Novartis Oncology; 2023 MM+M Gold Large Agency of the Year.

Mid-Size (50-200)

Specialty healthcare advertising agency with core focus on Oncology and rare disease/gene therapy; part of Avalere Health (the rebranded Fishawack Health network) since the October 2023 unification.

Boutique (<50)

Leading global healthcare communications agency in the WPP network; strong scientific PR, integrated communications, and patient engagement in Oncology.

Large (200+)

Oncology biovisualization and medical animation agency specializing in MOA animations and complex science visualization for cancer brands.

Boutique (<50)

Full-service global healthcare marketing agency combining show-stopping creative, strategic savvy, and deep scientific expertise; long-standing Oncology specialty roots dating to Avastin launch.

Large (200+)

Independent investor and corporate communications firm focused on life sciences; Oncology and rare disease IPO/launch and scientific narrative work.

Boutique (<50)

Full-service healthcare marketing agency with dedicated Oncology insights and HCP marketing practice serving large and emerging pharma.

Mid-Size (50-200)

Oncology-only full-service advertising agency — "transforming products into brands and patients into survivors." Part of Syneos Health Communications network.

Mid-Size (50-200)

Data-driven healthcare communications and commercial analytics company with Oncology launch expertise.

Large (200+)

Leading economic consulting firm with dedicated HEOR and epidemiology practice; significant Oncology evidentiary and litigation work.

Large (200+)

Global commercialization partner formed by the October 2023 rebrand of Fishawack Health (which had acquired the original Avalere policy/access consultancy in 2022); unified ~19 heritage agencies under one brand including Dudnyk, closerlook, 2e, Hive & Pollen, StoneArch, Skysis, Fire and Rain, PAI, and PRMA Consulting; strong Oncology, rare disease, market access, and medical affairs practice.

Large (200+)

Boutique RWE and HEOR consultancy partnering with life sciences companies across the product lifecycle; Oncology a core therapeutic area.

Boutique (<50)

Global management consulting with Oncology commercial strategy and market access advisory; includes former Navigant capabilities.

Large (200+)

Global CRO and consulting firm with dedicated market access and HEOR Oncology practice; 25+ years in managed markets.

Large (200+)

Boutique strategic HEOR and market access consultancy partnering with life sciences to overcome payer barriers and secure reimbursement.

Boutique (<50)

Global medical affairs partner with integrated HEOR and market access and medical communications capabilities; significant Oncology portfolio.

Large (200+)

Full-spectrum market access agency integrating HEOR evidence generation with payer strategy and medical communications; strong Oncology focus.

Mid-Size (50-200)

Strategic consultancy supporting biopharma with market access and HEOR; part of AmerisourceBergen/Cencora; active in Oncology pricing and access.

Mid-Size (50-200)

UK-based global healthcare communications group within Omnicom Health Group; strong Oncology, immunology, rare disease, and neurology track record across med ed, health outcomes, and reimbursement.

Large (200+)

Next-generation commercialization company for life sciences with a dedicated Oncology and hematology go-to-market division.

Large (200+)

Global full-service marketing agency network — part of EVERSANA — with deep Oncology brand work and digital-first capabilities.

Large (200+)

Creative and marketing agency within Inizio (the parent of Inizio Medical, Inizio Engage, and Inizio Evoke); full-service health communications with significant Oncology and rare disease capabilities.

Large (200+)

Global healthcare communications network under IPG; member agencies include McCann Health, FCB Health, and AREA 23 — all with Oncology brand teams.

Large (200+)

Independent full-service life sciences agency with deep clinical/commercial integration and strong Oncology specialty work.

Large (200+)

Global healthcare marketing network with Oncology-focused agencies including Navicor/GENICOS; full-service lifecycle commercial support.

Large (200+)

Oncology commercialization specialist supporting 280+ biopharma product launches; covers patient services and field force to market access.

Mid-Size (50-200)

Oncology-dedicated CME and CNE provider; delivers accredited online courses and activities for the multidisciplinary cancer care team.

Boutique (<50)

Omnichannel medical education company specializing in Oncology; acquired by The Lockwood Group in 2025.

Boutique (<50)

Leading Oncology media and education platform; publishes OncologyLive and Oncology Nursing News; AI-trained Oncology knowledge hub.

Mid-Size (50-200)

Jointly accredited CME/CNE/CPE provider with deep Oncology and hematology focus; produces peer exchange programs and live/virtual meetings.

Mid-Size (50-200)

Jointly accredited medical education provider with strong Oncology and hematology CME program portfolio.

Boutique (<50)

Oncology-only physician education company founded by medical oncologist; now part of The Lockwood Group.

Boutique (<50)

Rapidly expanding Oncology medical education company; acquired Research To Practice (RTP) and IDEOlogy Health and Total Health Oncology.

Mid-Size (50-200)

Clinical Oncology education company providing free programs to multidisciplinary cancer care teams; acquired by The Lockwood Group in 2026.

Boutique (<50)

EHR-integrated cancer care management software combining evidence-based guidelines with patient-reported outcomes for clinical decision support.

Boutique (<50)

Hub and patient support services company with Oncology capabilities; copay assistance and adherence programs.

Large (200+)

Global HCP programmatic digital media platform serving pharma; physician-only publisher network with strong Oncology reach.

Mid-Size (50-200)

Life sciences marketing partner leveraging Healio's 3M+ Oncology and specialty HCP audience for targeted pharma marketing.

Mid-Size (50-200)

Pioneer hub services provider with deep Oncology specialty; patient support programs including benefits verification and copay assistance.

Large (200+)

Leading Oncology patient management platform integrating EHR workflows with digital triage and patient engagement for cancer practices.

Boutique (<50)

Omnichannel digital health platform delivering pharma messaging via EHR and ePrescribing platforms; strong Oncology HCP engagement capabilities.

Mid-Size (50-200)